Urinary Metabolites as Biomarkers of Early Radiation Cystitis in Patients With Prostate Cancer Undergoing Radiotherapy.

IF 1.8 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

In vivo Pub Date : 2025-07-01 DOI:10.21873/invivo.14004

Sachika Shiraishi, Masahiro Sugimoto, Koichi Tokuuye

{"title":"Urinary Metabolites as Biomarkers of Early Radiation Cystitis in Patients With Prostate Cancer Undergoing Radiotherapy.","authors":"Sachika Shiraishi, Masahiro Sugimoto, Koichi Tokuuye","doi":"10.21873/invivo.14004","DOIUrl":null,"url":null,"abstract":"Background/aim: Treatment-related bladder toxicities are a primary concern in the management of prostate cancer radiotherapy. This study aimed to identify urinary metabolites that can predict early radiation cystitis-related toxicities in patients undergoing radiotherapy for prostate cancer.Patients and methods: Patients' clinical characteristics and urine samples were collected before, two weeks after, at the end, and three months after the initiation of radiotherapy and subsequently analyzed. Capillary electrophoresis-mass spectrometry and liquid chromatography-mass spectrometry were used for comprehensive quantification of urinary metabolites. Multivariate analysis was conducted to identify potential protective factors against the early toxicities of radiation cystitis.Results: A total of 176 samples were obtained from 44 patients. Betaine, tartrate, N,N-dimethylglycine, and homocarnosine were identified as independent protective factors against early toxicities of radiation cystitis among various potential confounding metabolic factors. Comorbid diabetes mellitus was also identified as a protective factor.Conclusion: Betaine, tartrate, N,N-dimethylglycine, and homocarnosine were identified as protective urinary metabolites against early radiation cystitis. Urinary metabolomic profiling may be a useful tool for investigating disease metabolism in metabolic disorders and cancers. Its ease of use and repeatability make it an optimal method for patient follow-up.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2091-2100"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223610/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14004","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Treatment-related bladder toxicities are a primary concern in the management of prostate cancer radiotherapy. This study aimed to identify urinary metabolites that can predict early radiation cystitis-related toxicities in patients undergoing radiotherapy for prostate cancer.

Patients and methods: Patients' clinical characteristics and urine samples were collected before, two weeks after, at the end, and three months after the initiation of radiotherapy and subsequently analyzed. Capillary electrophoresis-mass spectrometry and liquid chromatography-mass spectrometry were used for comprehensive quantification of urinary metabolites. Multivariate analysis was conducted to identify potential protective factors against the early toxicities of radiation cystitis.

Results: A total of 176 samples were obtained from 44 patients. Betaine, tartrate, N,N-dimethylglycine, and homocarnosine were identified as independent protective factors against early toxicities of radiation cystitis among various potential confounding metabolic factors. Comorbid diabetes mellitus was also identified as a protective factor.

Conclusion: Betaine, tartrate, N,N-dimethylglycine, and homocarnosine were identified as protective urinary metabolites against early radiation cystitis. Urinary metabolomic profiling may be a useful tool for investigating disease metabolism in metabolic disorders and cancers. Its ease of use and repeatability make it an optimal method for patient follow-up.

查看原文本刊更多论文

尿代谢物作为前列腺癌放疗患者早期放射性膀胱炎的生物标志物

背景/目的：治疗相关的膀胱毒性是前列腺癌放疗管理的主要问题。本研究旨在确定能够预测前列腺癌放疗患者早期放射性膀胱炎相关毒性的尿液代谢物。患者与方法：收集放疗前、放疗后2周、放疗结束时、放疗后3个月患者的临床特征及尿液样本，并进行分析。采用毛细管电泳-质谱法和液相色谱-质谱法对尿液代谢物进行综合定量分析。通过多变量分析来确定对放射性膀胱炎早期毒性的潜在保护因素。结果：44例患者共采集标本176份。甜菜碱、酒石酸盐、N、N-二甲基甘氨酸和同型肌肽在多种潜在的混杂代谢因子中被确定为抗放射性膀胱炎早期毒性的独立保护因子。合并症糖尿病也被认为是一个保护因素。结论：甜菜碱、酒石酸盐、N、N-二甲基甘氨酸和正肌肽是早期放射性膀胱炎的保护性尿代谢物。尿代谢组学分析可能是研究代谢紊乱和癌症疾病代谢的有用工具。它的易用性和可重复性使其成为患者随访的最佳方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

In vivo 医学-医学：研究与实验

CiteScore

4.20

自引率

4.30%

发文量

330

审稿时长

3-8 weeks

期刊介绍： IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.